Sana Biotechnology, Inc. (SANA) Stock Analysis
A live, multi-source view of Sana Biotechnology, Inc. (SANA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
Sector: Healthcare · Industry: Biotechnology · United States · 142 employees · sana.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Sana Biotechnology, Inc. (SANA) had a market capitalization of $1.15B (forward -6.9) and a beta of 2.13; the shares traded in a 52-week range of $2.61 – $6.55 (28.3% over the year).
- Market cap
- $1.15B
- Enterprise value
- $1.07B
- Forward P/E
- -6.9
- Price / book
- 8.71
- EPS (trailing)
- $-0.75
- EPS (forward)
- $-0.56
- Payout ratio
- 0.0%
- 52-week range
- $2.61 – $6.55
- 52-week change
- 28.3%
- Beta
- 2.13
- Average volume
- 3.0M
- Shares outstanding
- 299.4M
- Short % of float
- 24.00%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Sana Biotechnology, Inc. (SANA) last closed at $3.17 (the last completed close before that scan).
Technicals at the scan: RSI 36 (neutral territory), price -16.6% versus its 20-day average, 20-day versus 50-day average spread +5.3%, MACD histogram -0.08.
Sentiment inputs: StockTwits 91% bullish; analyst consensus score 78/100.
Next scheduled company event: in 56 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for SANA in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
SANA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Sana Biotechnology, Inc. (SANA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell SANA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.